• 약학회지
• /
• 제54권4호
• /
• pp.309-315
• /
• 2010

The Positive List System was newly introduced in South Korea as of January 2007. This study aims to survey and compare perception of and attitudes toward the Positive List System in the process of new drug listing that health professionals and pharmaceutical companies have. 50 professionals and 52 companies answered the questionnaire regarding health policy environments, policy decision/enforcement process, policy effects and satisfaction related to introducing the Positive List System. SAS 9.1 was used for statistical analyses. The results showed that participants had the general sympathy with health policy environments for the introduction of the Positive List System into South Korea. However, the response rates of policy decision/enforcement process and effects were negative and these tendencies were more striking in pharmaceutical companies. As for policy satisfaction, participants marked positive responses more than negative ones. It is necessary to remedy and supplement problems with policy decision/enforcement policy and effects revealed in this study and to improve the Positive List System through gathering opinions among groups and organization concerned.

• 약학회지
• /
• 제55권4호
• /
• pp.338-344
• /
• 2011

This study aimed to identify the changes in the list of drugs covered by national health insurance(NHI) after the introduction of positive list system (PLS) in Korea in December, 2006. Six-year (pre-policy:2004-2006, post-policy:2007-2009) lists of the NHI reimbursable drugs filed from Health Insurance Review and Assessment Service (HIRA) were analyzed. The total number of listed drugs as well as drug ingredients, and the average number of listed drugs per manufacturer decreased annually after the introduction of PLS. More than 8,000 drugs were delisted in the year 2007 right after the policy change. Prescription-only drugs occupied more than 85% of NHI listed drugs. The percentage of oral type of listed drugs has been increased to more than 60% after the policy change. Korean pharmaceutical manufacturers occupied more than 90% of listed drugs than multinational firms. The gap between Korean and foreign manufacturer in terms of the average number of newly listed drugs per manufacturer in each year has decreased two years after the PLS (Korean 7.7 vs. foreign 6.3 in 2009) as the price negotiation power of foreign firms has increased. The total number of listed drugs is expected to decrease in the future as the Korean government makes an effort to delist the unnecessary drugs that do not show cost-effectiveness.

• 월간포장계
• /
• 통권158호
• /
• pp.58-67
• /
• 2006

• 월간포장계
• /
• 통권140호
• /
• pp.148-168
• /
• 2004

• Journal of Preventive Medicine and Public Health
• /
• 제41권2호
• /
• pp.69-73
• /
• 2008

To curb a rapid increase in expenditures for pharmaceuticals, the Korean government introduced a positive list system and a negotiation process for drug prices at the end of 2006. Economic evaluation of pharmaceuticals has begun to have a pivotal role in the listing and pricing of drugs for the Korean National Health Insurance. There are some points to discuss regarding the use of economic evaluation in the listing and pricing in the context of the Korean system. First, the listing and pricing processes have been fragmented, evoking complaints from pharmaceutical companies and delaying the access of new drugs to patients. Second, there is a concern that the positive list system may limit the range and availability of drugs for patients to choose for treatment. Third, the time schedule for de-listing of existing drugs may not be realistic. Fourth, it is not always easy to provide reliable evidence of cost-effectiveness due to a lack of materials. Fifth, there is no consensus on the range of the ICER (incremental cost-effectiveness ratio) acceptable to the Korean society. In conclusion, in the near future, it will be necessary to evaluate the achievements that the economic evaluation has provided to the Korean society.

• Kyungpook Mathematical Journal
• /
• 제63권3호
• /
• pp.355-372
• /
• 2023

We make advances towards a structural characterisation of the signed graphs H for which the list switch H-colouring problem List-S-Hom(H) can be solved in polynomial time. We conjecture two different characterisations, the second refining the first, in the case that the graph H can be switched to a graph in which every negative edge is also positive. Using a recent proof of the first characterisations for reflexive signed graphs, by Bok et. al., we prove the second characterisation for reflexive signed graphs. We also provide several tools for reducing the problem to the bipartite case, and prove a full complexity dichotomy for a related problem.

• 월간포장계
• /
• 통권207호
• /
• pp.75-89
• /
• 2010

• 월간포장계
• /
• 통권327호
• /
• pp.72-77
• /
• 2020

• 대한화장품학회지
• /
• 제28권3호
• /
• pp.109-145
• /
• 2002

Council Directive 76/768/EEC는 EU에서 화장품에 대한 기본적인 규정에 대한 기초가 된다. 이 규정의 배경과 원리에 대한 간단한 소개 후에 주요안건에 대해 강연할 것이다. 특히, 안전성에 대한 기본적인 원칙에 대해 주로 다루었으며, 6차 개정 이행(Council Directive 93/3S/EC)에 따른 영향에 대하여 분석 하였다. 토론의 주요 주제는 화장품의 안전성에 대한 요건과 EU시장에서 화장품 출시시 최종적인 책임, 개개의 성분의 안전성을 기초로 한 최종제품의 안전성에 대한 EU의 개념, 모든 최종제품에 대한 유럽에서 요구하는 서류와 개개의 성분들의 positive list와 negative list의 존재여부에 대하여 다루어지며 또한 주요관심인 7차 개정에 의해 새롭게 제안된 것과 동물대체시험법의 사용에 대해 강연할 것이다. 마지막으로, positive list에 존재하는 성분의 경우 SCCNFP에 의하여 이루어지는 안전성평가와 최종 제품에 대한 기술적인 측면에서 안전성평가자로서 이루어지는 평가에 대해 상세하게 다루어 질 것이다.

• 대한수학회지
• /
• 제45권3호
• /
• pp.621-630
• /
• 2008

In this paper, we provide a complete list of 177 equivalence classes of primitive even 2-regular quaternary positive definite quadratic forms and their discriminants. All of them have class number 1.